The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Mereo Biopharma Group Plc ADR (NASDAQ: MREO) was $4.01 for the day, down -6.31% from the previous closing price of $4.28. In other words, the price has decreased by -$6.31 from its previous closing price. On the day, 0.77 million shares were traded. MREO stock price reached its highest trading level at $4.24 during the session, while it also had its lowest trading level at $4.01.
Ratios:
Our analysis of MREO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.07 and its Current Ratio is at 6.07. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on June 13, 2024, initiated with a Outperform rating and assigned the stock a target price of $8.
On August 12, 2022, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $4.Cantor Fitzgerald initiated its Overweight rating on August 12, 2022, with a $4 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 13 ’24 when Scots-Knight Denise sold 60,046 shares for $4.22 per share. The transaction valued at 253,454 led to the insider holds 808,921 shares of the business.
Scots-Knight Denise sold 28,611 shares of MREO for $127,968 on Sep 12 ’24. The Chief Executive Officer now owns 868,967 shares after completing the transaction at $4.47 per share. On Sep 13 ’24, another insider, Lewicki John A., who serves as the Chief Scientific Officer of the company, sold 10,937 shares for $4.22 each. As a result, the insider received 46,165 and left with 78,630 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MREO now has a Market Capitalization of 616950528 and an Enterprise Value of 2998512640. Its current Enterprise Value per Revenue stands at 2998.513 whereas that against EBITDA is -80.365.
Stock Price History:
Over the past 52 weeks, MREO has reached a high of $5.02, while it has fallen to a 52-week low of $1.86. The 50-Day Moving Average of the stock is -7.70%, while the 200-Day Moving Average is calculated to be 7.31%.
Shares Statistics:
MREO traded an average of 792.10K shares per day over the past three months and 533890 shares per day over the past ten days. A total of 153.76M shares are outstanding, with a floating share count of 141.76M. Insiders hold about 7.81% of the company’s shares, while institutions hold 57.57% stake in the company. Shares short for MREO as of 1728950400 were 5158385 with a Short Ratio of 6.51, compared to 1726185600 on 4541368. Therefore, it implies a Short% of Shares Outstanding of 5158385 and a Short% of Float of 3.9800000000000004.
